Patient-Reported Outcomes
Cross-source consensus on Patient-Reported Outcomes from 1 sources and 5 claims.
1 sources · 5 claims
Comparisons
Other
Other
Other
Highlighted claims
- EPIC-26 scores range from 0 to 100, with higher scores indicating better function. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- The primary outcome is detection of a minimally important difference in EPIC-26 score relative to pretreatment baseline. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- EPIC-26 is collected repeatedly after treatment through annual follow-up to 5 years. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Secondary patient-reported instruments include IPSS, IIEF-5/SHIM, and the Vaizey Incontinence Score. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- The trial hypothesis is that acute toxicity and late toxicity will not differ significantly between treatment arms. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer